



February 17, 2021

Dear CLN1 Batten Community,

As you may have seen, Taysha recently provided an update about TSHA-118, our investigational gene therapy for the treatment of CLN1 disease, a form of Batten disease. Some gene therapies try to replace or repair a missing or dysfunctional gene that causes disease. In the case of TSHA-118, the goal is to deliver a functional copy of the CLN1 gene into cells in the body, with the hope of providing cells with the genetic 'instructions' they need to function properly. The American Society of Gene & Cell Therapy (ASGCT) has educational information on gene therapy located [here](#).

To prepare for meetings with FDA, Taysha has met with Batten disease physicians and parents to provide an understanding of CLN1 disease diagnosis, symptoms and management. We expect these discussions will provide keen insight in refining the clinical trial protocol. We plan to work closely with FDA in the hopes of initiating a Phase 1/2 clinical trial for TSHA-118 in CLN1 in the second half of 2021. We are also considering conducting a study outside of the United States, but timing of this has not yet been determined.

"We are committed to carefully advancing the science to move TSHA-118 into clinical development. We recognize the CLN1 community is eager for potential therapies for this devastating disorder, and we are moving as safely and efficiently as we can."

- RA Session II, Founder, President & CEO, Taysha Gene Therapies

We are encouraged by the strength of the Batten communities and look forward to updating you through our advocacy partners as information becomes available. Working together, we can continue to deepen our understanding of this disease.

Warm regards,

The Taysha Team

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Taysha's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely, including those described in our filings with the Securities and Exchange Commission, which is available at www.sec.gov. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.